Iloprost Therapy in Patients With Critical Limb Ischemia

Bayer

Status: Completed

Conditions: Peripheral Arterial Disease

Treatments: Drug: Iloprost (Ilomedin, BAYQ6256)

Study type: Observational

Funder types: Industry

Identifiers

NCT01458041

15439

VE1011HU (Other Identifier)

Details and patient eligibility

About

Monitoring efficacy and safety aspects of iv. iloprost therapy of patients with critical limb ischemia by recording clinical parameters.

Enrollment: 126 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who fulfill the internationally defined criteria of critical limb ischemia;
• Patients who are not eligible for vascular surgery or angioplasty interventions and
• Patients who are treated with iloprost infusion.
• The treating physician has decided iloprost treatment before study enrollment.

Exclusion criteria

• Exclusion criteria are in accordance with the Summary of Product Characteristics of Ilomedin.

Trial design

126 participants in 1 patient group

Group 1

Treatment:

Drug: Iloprost (Ilomedin, BAYQ6256)